SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksContext Vision Regulatory News (0L8Z)

Share Price Information for Context Vision (0L8Z)

Share Price is delayed by 15 minutes
Get Live Data
3.08    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap:
0L8Z Live PriceLast checked at - London Stock Exchange

Intraday Context Vision Share Chart

  • This share is an international stock.

ContextVision AB: Transactions made under the buy-back programme

7 Jan 2026 17:36

Oslo, 7 January 2026 - On 3 September, ContextVision AB ("ContextVision" or the "Company") announced a share buy-back programme of up to NOK 10,000,000, with a maximum of 4,000,000 shares, in the period from 5 September 2025 to 5 March 2026.DNB Carnegie, acting under the mandate from ContextVision, has carried out the following transactions under the buy-back programme:

DateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)
2025-12-234 1784,043417 111,00
2025-12-293 1774,220213 788,18
2025-12-3010 2734,162343 283,23
2026-01-0210 5254,145143 883,99
2026-01-051513,9570608,53
2026-01-064 3323,938017 161,22
2026-01-079 4463,979737 682,93
Previously disclosed buy-buys under the programme (accumulated)683 2444,10932 913 607,78
Accumulated under the buy-back programme725 3264,10553 087 126,85

 

Following the completion of the above transactions, ContextVision owns a total of 2 103 488 of own shares, corresponding to 2,72% of ContextVision's share capital. 

An overview of all transactions made under the buy-back programme that have been carried out during the abovementioned time period is attached to this report and available at www.newsweb.no .This is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Richard Hallström, CFO, on the time and date provided.

For further information, please contact:Richard Hallström, CFOEmail: richard.hallstrom@contextvision.com About ContextVision AB:ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-07 18:36 CET.

AttachmentsContextVision AB: Transactions made under the buy-back programmeDetailed Overview Of Buy Back 260107

Date   Source Headline
12th May 20263:35 pmMFNContextVision: BULLETIN FROM THE ANNUAL GENERAL MEETING OF CONTEXTVISION AB (PUBL)
11th May 20263:34 pmMFNContextVision: ContextVision AB: Transactions made under the buy-back programme
8th May 20266:00 amMFNContextVision: ContextVision AB: Q1 interim report 2026 - Solid progress and disciplined execution in a stabilising market
29th Apr 20263:14 pmMFNContextVision: ContextVision AB: Transactions made under the buy-back programme
24th Apr 20266:00 amMFNContextVision: Correction: Annual report financial calendar â€" Q1 interim report date
20th Apr 20263:16 pmMFNContextVision: ContextVision AB: Transactions made under the buy-back programme
9th Apr 20264:38 pmMFNContextVision AB: Transactions made under the buy-back programme
8th Apr 20266:00 amMFNContextVision publishes annual report for the fiscal year 2025
7th Apr 20265:30 amMFNContextVision cancels market-making agreement
26th Mar 20264:20 pmMFNContextVision AB: Transactions made under the buy-back programme
17th Mar 20266:05 pmMFNContextVision AB: Transactions made under the buy-back programme
6th Mar 20267:48 pmMFNContextVision AB: Transactions made under the buy-back programme
25th Feb 20264:04 pmMFNContextVision AB: Transactions made under the buy-back programme
19th Feb 20267:00 amMFNContextVision AB: Year-end report 2025 - Substantial progress in transformation amid early signs of stabilization
18th Feb 20263:50 pmMFNContextVision announces extended share buy-back programme
16th Feb 20264:16 pmMFNContextVision AB: Transactions made under the buy-back programme
5th Feb 20264:00 pmMFNContextVision AB: Transactions made under the buy-back programme
27th Jan 20264:17 pmMFNContextVision AB: Transactions made under the buy-back programme
16th Jan 20264:26 pmMFNContextVision AB: Transactions made under the buy-back programme
7th Jan 20265:36 pmMFNContextVision AB: Transactions made under the buy-back programme
22nd Dec 20254:25 pmRNSContextVision AB: Transactions made under the buy-back programme
22nd Dec 20254:25 pmMFNContextVision AB: Transactions made under the buy-back programme
11th Dec 20254:08 pmMFNContextVision AB: Transactions made under the buy-back programme
2nd Dec 20255:45 pmMFNContextVision AB: Transactions made under the buy-back programme
12th Nov 20254:11 pmMFNContextVision AB: Transactions made under the buy-back programme
6th Nov 20257:00 amMFNContextVision AB: Q3 interim report 2025 - Navigating market uncertainty while making solid progress with our Data Quality initiative
22nd Oct 20207:00 amGNWContextVision’s third quarter sees a recovery in sales and market entry in digital pathology is on track

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.